stockrowCartesian Therapeutics, Inc.
RNACCartesian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 92.8% from fiscal 2024.
- Revenue
- −92.9%
- EPS
- −7.84%
- Free cash flow
- −6.15%
Quarter to June 2026, against a year earlier
Follow RNAC
Alert me
Cartesian Therapeutics, Inc. (RNAC) EV/Sales
As of 6 November 2026, Cartesian Therapeutics, Inc. (RNAC) trades at a EV/Sales of 77.4×. Over the past ten years it has ranged from −5.4× (August 2016) to 1,595× (December 2019); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 30.8× | 347.04% |
| FY2024 | 6.9× | 249.88% |
| FY2023 | 2.0× | 509.47% |
| FY2022 | 0.3× | (87.52%) |
| FY2021 | 2.6× | (60.51%) |
| FY2020 | 6.6× | 0.16% |
| FY2019 | 6.5× | (97.61%) |
| FY2018 | 274× | (48.46%) |
| FY2017 | 532× | 4,967.41% |
| FY2016 | 10.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 39.7× | 29.03% |
| Dec 2025 | 30.8× | (77.05%) |
| Sep 2025 | 134× | 3.02% |
| Jun 2025 | 130× | 2,306.05% |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| PLX Protalix BioTherapeutics, Inc. compare | 2.3× |
| RNAC Cartesian Therapeutics, Inc. | 77.4× |
| SLGL Sol-Gel Technologies Ltd. compare | 121× |
| PALI Palisade Bio, Inc. compare | 151× |
| IKT Inhibikase Therapeutics, Inc. compare | 395× |
| IFRX InflaRx N.V. compare | 1,845× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)